Shares of OpGen Inc (NASDAQ:OPGN) have been given an average broker rating score of 1.00 (Strong Buy) from the two analysts that cover the stock, Zacks Investment Research reports. Two investment analysts have rated the stock with a strong buy rating.

Analysts have set a one year consensus target price of $5.60 for the company and are expecting that the company will post ($0.53) EPS for the current quarter, according to Zacks. Zacks has also given OpGen an industry rank of 100 out of 255 based on the ratings given to its competitors.

A number of analysts have recently weighed in on OPGN shares. HC Wainwright set a $8.00 target price on OpGen and gave the company a “buy” rating in a research report on Friday, August 3rd. ValuEngine upgraded OpGen from a “hold” rating to a “buy” rating in a research report on Tuesday, July 10th. Finally, Zacks Investment Research upgraded OpGen from a “sell” rating to a “buy” rating and set a $2.25 target price for the company in a research report on Wednesday, July 11th.

An institutional investor recently bought a new position in OpGen stock. B. Riley Financial Inc. purchased a new position in shares of OpGen Inc (NASDAQ:OPGN) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 138,000 shares of the medical research company’s stock, valued at approximately $246,000. B. Riley Financial Inc. owned approximately 2.22% of OpGen as of its most recent filing with the SEC. Hedge funds and other institutional investors own 11.36% of the company’s stock.

Shares of NASDAQ:OPGN traded up $0.01 during trading on Friday, reaching $1.95. 103,429 shares of the company traded hands, compared to its average volume of 327,464. The company has a market cap of $12.61 million, a price-to-earnings ratio of -0.20 and a beta of 1.51. The company has a debt-to-equity ratio of 0.19, a quick ratio of 1.99 and a current ratio of 2.13. OpGen has a 52 week low of $1.62 and a 52 week high of $10.25.

OpGen (NASDAQ:OPGN) last released its earnings results on Thursday, August 2nd. The medical research company reported ($0.57) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.60) by $0.03. The firm had revenue of $0.79 million during the quarter, compared to the consensus estimate of $0.79 million. OpGen had a negative return on equity of 241.59% and a negative net margin of 373.39%. Research analysts predict that OpGen will post -2.13 EPS for the current fiscal year.

OpGen Company Profile

OpGen, Inc, a precision medicine company, engages in developing molecular information products and services to combat infectious diseases in the healthcare industry worldwide. The company utilizes molecular diagnostics and bioinformatics to help combat infectious diseases. It also helps clinicians with information about life threatening infections, enhance patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms.

Featured Article: Return on Investment (ROI)

Get a free copy of the Zacks research report on OpGen (OPGN)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for OpGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen and related companies with's FREE daily email newsletter.